Nuvation Bio Inc.
NUVB
Positions held
Your positionsNUVB isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Nuvation Bio Inc. operates in a competitive biotechnology sector with potential for growth as it develops innovative therapies.
- The company's market cap stands at approximately $1.71 billion, indicating significant investor interest.
- Despite recent challenges, Nuvation's gross margin was 70.1% in Q2 2026, down from 92.8% in Q1 2026.
- Nuvation Bio faces significant financial challenges, with a profit margin of -88.2% and a net income loss of $62.84 million in Q2 2026.
- The company's operating margin has been negative, reaching -161.1% in Q2 2026, indicating operational inefficiencies.
- Revenue dropped by 62% compared to the prior quarter, from $83 million to $32 million.
Fundamentals
| Market cap | $1.74B | Enterprise value | $1.49B | Trailing P/E | — | Forward P/E | -330.00 |
| PEG | — | Price / book | 6.82 | Beta | 1.62 | Dividend yield | 0.00% |
| Revenue growth | 5.6% | Earnings growth | — | Gross margin | 88.2% | Operating margin | -1.6% |
| Profit margin | -88.2% | ROE | -47.8% | ROA | -12.4% | Debt / equity | 1.64 |
| Current ratio | 8.37 | Free cash flow | -$112.11M | Analyst recommendation | strong_buy | Mean target | $13.00 |
| 52w high | $9.75 | 52w low | $3.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $31.7M | $83.2M | $41.9M | $13.1M | $4.8M |
| Op margin | -161.1% | 4.7% | -81.3% | -430.1% | -1315.7% |
| Net income | -$62.8M | $5.4M | -$36.6M | -$55.8M | -$59.0M |
| Gross margin | 70.1% | 92.8% | 96.9% | 74.5% | 46.7% |
| Gross profit | $22.2M | $77.2M | $40.6M | $9.8M | $2.3M |
| Operating income | -$51.0M | $3.9M | -$34.0M | -$56.4M | -$63.6M |
- Revenue -62% vs prior quarter ($32M vs $83M).
- Gross margin 70.1% (was 92.8% prior quarter).
- Operating margin compressed to -161.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0.0M | $0.0M | — |
| Op margin | -338.7% | -2128.2% | — | — | — |
| Net income | -$205M | -$568M | -$75.8M | -$104M | — |
| Gross margin | 85.2% | 10.1% | — | — | — |
| Gross profit | $53.6M | $0.8M | $0.0M | — | — |
| Operating income | -$213M | -$168M | -$99.8M | -$120M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-03 · Top Penny Stocks To Own In October 2026
2026-09-30 · Citigroup Initiates Nuvation Bio at Buy With $12 Price Target
2026-09-17 · Sector Update: Healthcare Stocks Rise Thursday Afternoon
2026-09-17 · Sector Update: Healthcare Stocks Edge Higher Pre-Bell Thursday
2026-09-17 · Sector Update: Healthcare
2026-09-17 · Nuvation Bio Gets FDA Approval for Updated IBTROZI Label
2026-09-16 · Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups
2026-09-06 · Jim Cramer sends strong 5-word message on surging biotech stock
2026-09-03 · Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
2026-09-02 · Nuvation Bio to Participate in Upcoming Investor Conferences
Price (daily)
Full chart · RSI · MACD · patterns